Table 2.
Patient characteristics part II:
| Pat.No. | Systemic therapy of primary disease | Systemic therapy of secondary disease | Recurrent tumour size (mm) | Applicator size IORT (cm) | Dose IORT (Gy) | Treatment time IORT (Min) |
| 1 | GnRH | Tamoxifen | 12 | 3.5 | 20,0 | 18,60 |
| 2 | 6 × CMF | AI | 35 | 5.0 | 14,7 | 35,90 |
| 3 | None | GnRH | 1 | 3.5 | 20,0 | 18,60 |
| 4 | Tamoxifen | AI | 16 | 4.5 | 14,7 | 28,70 |
| 5 | Tamoxifen | AI | 16 | 4.5 | 14,7 | 28,70 |
| 6 | Tamoxifen | AI | 12 | 4.0 | 20,0 | 26,80 |
| 7 | None | AI | 8 | 3.0 | 20,0 | 24,98 |
| 8 | None | Tamoxifen | 7 | 4.0 | 20,0 | 26,80 |
| 9 | 6× CMF + Tam | AI | 15 | 4.0 | 20,0 | 26,80 |
| 10 | 3× CMF + Tam | AI | 18 | 4.0 | 20,0 | 26,80 |
| 11 | None | Tam | 10 | 4.0 | 20,0 | 28,26 |
| 12 | None | AI | 9 | 3.5 | 20,0 | 19,9 |
| 13 | None | none | 11 | 5.0 | 20,0 | 49,5 |
| 14 | None | none | 11 | 3.5 | 20,0 | 19,9 |
| 15 | 4× EC + Tam | AI + GnRH | 11 | 3.0 | 20,0 | 26,4 |
| 16 | 4× ABVD | leftTamoxifen | 11 | 2.5 | 20,0 | 19,2 |
| 17 | none | 4 × FEC | 11 | 5.0 | 20 | 49.50 |
GnRH = Gonadotropin Releasing-Hormone Analoga, Tam = Tamoxifen, CMF = Cyclophosphamide (600 mg/m2)/Methotrexate (40 mg/m2)/5-Fluorouracil (600 mg/m2)
EC = Epirubicin (90 mg/m2)/Cyclophosphamide (600 mg/m2), AI = Aromatase inhibitors
ABVD = Adriamycin, Bleomycin, Vinblastin, DTIC